Amwell Q3 adjusted EBITDA loss narrows 72% year over year to $3.6 million

By Public Technologies
  • Amwell’s Q3 2026 adjusted EBITDA loss narrowed 72% year-over-year to $3.6 million.
  • The company raised its 2026 adjusted EBITDA outlook to a loss of $7 million to $8 million.
  • Q4 2026 adjusted EBITDA is expected to range from breakeven to $1 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. American Well Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031605PRIMZONEFULLFEED9868881) on November 03, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk